Company intelligence / Profile preview

Memory Pharmaceuticals

Nutley or Montvale, New Jersey, United Statesbloomberg.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Memory Pharmaceuticals developed small molecule drug candidates targeting central nervous system disorders, with its lead programs focused on nicotinic alpha-7 agonists for Alzheimer's disease and schizophrenia. At the time of its acquisition by Roche in late 2008, its most advanced program was in Phase II clinical trials for these indications[1][3].

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (notably nicotinic alpha-7 agonists)[1][3]
Industry: Biotech

Drug pipeline

1 asset

MEM 3454

Phase 2

Indications: Cognitive impairment associated with schizophrenia, Alzheimer's disease

Partnerships

Roche was a key partner prior to full acquisition; partnered on development of CNS drug candidates[1].

Beyond the preview

Go deeper on Memory Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Memory Pharmaceuticals.

Explore the full profile